Itzhak Kurek, PhD is CEO & Co-Founder of Cannformatics. Itzhak and his team are measuring the effectiveness of cannabis-based medicines using biomarkers. So far, they have identified dozens of cannabis-responsive biomarkers that can be used to objectively quantify the physiological impact of medical cannabis treatment and provide a tool for investigating the metabolic pathways affected by medical cannabis and CBD. Their pilot study looked at patients with Autism Spectrum Disorder and was published in the journal Cannabis and Cannabinoid Research in December. 

During our conversation, we discussed: 

Thank You to This Episode’s Sponsor: Cannabis Patient Care

Cannabis Patient Care magazine is an educational resource for patients, medical professionals, caregivers, and advocates on the latest research, benefits, and treatment options medical cannabis provides for a variety of illnesses. 

Learn more at cannapatientcare.com

Additional Resources